PAPERS CITED IN POWERPOINT SLIDES
Attal M et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349(26):2495-502. Abstract
Augustson BM et al. Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002— Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23(36):9219-26. Abstract
Bladé J et al. Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158(17):1889-93. Abstract
Child JA et al; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348(19):1875-83. Abstract
Desikan R et al. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95(12):4008-10. Abstract
Dimopoulos MA et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010). Proc ASH 2005. Abstract 6
Dimopoulos MA et al. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004;117(7):508-15. Abstract
Dimopoulos MA et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001;12(7):991-5. Abstract
Fonseca R et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res 2002;62(3):715-20. Abstract
Harousseau JL et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 2006a;91(11):1498-505. Abstract
Harousseau JL et al. VELCADE/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): An interim analysis of the IFM 2005-01 randomized multicenterphase III trial. Proc ASH 2006b. Abstract 56
Jagannath S et al. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Proc ASH 2006. Abstract 796
Jagannath S et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005;103(6):1195-200.Abstract
Kane RC et al. United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy. ClinCancer Res 2006;12(10):2955-60. Abstract
Knudsen LM et al. Autologous stem cell transplantation in multiple myeloma: Outcome in patients with renal failure. Eur J Haematol 2005;75(1):27-33. Abstract
Knudsen LM et al. Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000;65(3):175-81. Abstract
Kröger N et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004;103(11):4056-61. Abstract
Kyle RA et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78(1):21-33. Abstract
Lacy MQ et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82(10):1179-84. Abstract
Marriott JB et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002;130(1):75-84. Abstract
Mateos MV et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93(4):560-5.Abstract
Mateos MV et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 2006;108(7):2165-72. Abstract
Mitsiades N et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002;99(12):4525-30. Abstract
Orlowski RZ et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105(8):3058-65. Abstract
Palumbo A et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006;367(9513):825-31. Abstract
Palumbo A et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood 2004;104(10):3052-7. Abstract
Pineda-Roman M et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008;22(7):1419-27. Abstract
Rajkumar SV et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106(13):4050-3. Abstract
Richardson PG et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 2007a;110(10):3557-60. Abstract
Richardson P et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a Phase II study. Proc ASH 2007b. Abstract 2714
Richardson PG et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108(10):3458-64. Abstract
Richardson PG et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352(24):2487-98. Abstract
Richardson PG et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 2007;110(10):3557-60. Abstract
Richardson PG et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348(26):2609-17. Abstract
Richardson PG et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100(9):3063-7. Abstract
Seong C et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998;101(1):189-94. Abstract
Singhal S et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341(21):1565-71. Abstract
Torra R et al. Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995;91(4):854-9. Abstract
Tricot G et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997;15(7):2659-66. Abstract
Wang M et al. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007;12(3):235-9. Abstract
Weber DM et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiplemyeloma (MM): Results of a North American phase III study (MM-009). Proc ASCO 2006. Abstract 7521
Zangari MTG et al. Results of phase 1 study of CC-5013 for the treatment of multiple myeloma patients who relapse after high dose chemotherapy. Proc ASH 2001. No abstract available
| Table of Contents | Top of Page |
